Gene Synthesis Market Size & Forecasts 2026-2035, By Segments (Method, Type, Component, Application), Growth Opportunities, Innovation Landscape, Regulatory Shifts, Strategic Regional Insights (U.S., Japan, China, South Korea, UK, Germany, France), and Competitive Dynamics (Thermo Fisher Scientific, Twist Bioscience, Eurofins Genomics, Integrated DNA Technologies, GenScript)

Market Size and Growth Outlook

Gene Synthesis Market size is likely to expand from USD 11.19 billion in 2025 to USD 79.1 billion by 2035, posting a CAGR above 21.6% across 2026-2035. The industry’s revenue potential for 2026 is USD 13.39 billion.

• Base Year Value (2025): USD 11.19 billion
• CAGR (2026-2035): 21.6%
• Forecast Year Value (2035): USD 79.1 billion
• Historical Data Period: 2022-2025
• Largest Region: North America
• Forecast Period: 2026-2035

Key Takeaways

• North America region gained around 39% revenue share in 2025, driven by the expanding field of synthetic biology and interest in gene therapy development.
• North America region will achieve around 24.15% CAGR from 2026 to 2035, accelerated by the presence of key players and robust R&D investment in genomics.
• In 2025, the oligonucleotides segment accounted for majority share of the gene synthesis market, driven by widespread use of oligonucleotide synthesis across research and diagnostic workflows.
• The gene library synthesis segment dominated the market in 2025, supported by demand for comprehensive libraries in high-throughput genomic analysis.
• In 2025, the product segment contributed the largest share to the gene synthesis market, driven by sales of synthesis instruments and reagents central to gene construction workflows.
• The research and development segment led the market in 2025, propelled by extensive use in R&D for novel therapeutics and genetic tools.
• Major competitors in the gene synthesis market include Thermo Fisher Scientific (USA), Twist Bioscience (USA), Eurofins Genomics (Luxembourg), Integrated DNA Technologies (USA), GenScript (China), Agilent Technologies (USA), Syntezza Bioscience (Israel), Bioneer (South Korea), Sangon Biotech (China), BioBasic (Canada).

Market Growth Drivers and Industry Trends

Increasing Demand for Synthetic Genes in Biotech Applications

The rising need for synthetic genes driven by advancements in biotechnology is a critical growth driver shaping the gene synthesis market. Innovations in gene editing and personalized medicine are heightening demand for precise and customizable genetic constructs, as observed in recent developments by Integrated DNA Technologies. This shift is reshaping research paradigms and therapeutic development, enabling faster design-to-production cycles. Established players benefit by deepening partnerships with pharmaceutical and agricultural firms, while new entrants can target niche applications such as microbial engineering. As biotechnological methods evolve, this trend continues to stimulate market diversification grounded in enhanced gene synthesis capabilities, manifesting in growing cross-sector collaborations.

Technological Innovations in Gene Synthesis Platforms

Breakthroughs in automation, error correction, and scalable synthesis technologies are revolutionizing the gene synthesis market’s efficiency and cost-effectiveness. For example, Twist Bioscience’s semiconductor-based DNA synthesis technology exemplifies how digital transformation optimizes production throughput and quality, reducing barriers to entry. These innovations facilitate rapid prototyping and complex gene assembly, catering to both industrial biotechnology and academic research demands. Companies able to integrate advanced platforms stand to expand application scope and improve turnaround times, while emerging firms can leverage modular or cloud-based synthesis models. This technology-driven progression ensures continuous refinement in precision and scalability, reinforcing competitiveness and broadening market access globally.

Global Expansion of Research and Industrial Applications

The gene synthesis market is increasingly fueled by geographic and sectoral expansion in research and industrial use cases. Governments like the U.S. National Institutes of Health (NIH) and the European Commission are amplifying funding for synthetic biology and industrial biotech, invigorating adoption across pharmaceuticals, agriculture, and biofuels. This broadening ecosystem enhances innovation pipelines and creates pressure for localized synthesis capabilities in emerging markets. Established companies gain strategic advantage through regional collaborations and customized solutions, whereas startups can capitalize on unmet needs in underpenetrated territories. This macro-scale proliferation of gene synthesis underscores a trend toward diversified application portfolios driven by global policy support and market liberalization.

Industry Restraints:

Stringent Biosecurity and Regulatory Oversight

Biosecurity concerns and the complex regulatory landscape significantly slow the gene synthesis market’s growth by imposing rigorous compliance protocols to prevent misuse of synthetic DNA technologies. Agencies like the U.S. Department of Health and Human Services (HHS) through the Genetic Sequence Screening Framework mandate thorough screening of synthetic DNA orders to control potential bioterrorism risks, introducing operational delays and increased costs. Such stringent regulations hinder market agility, particularly for startups lacking resources to navigate multi-jurisdictional compliance, thereby favoring incumbents with established compliance infrastructures. As oversight frameworks evolve amid rising dual-use concerns, regulatory scrutiny will intensify, necessitating robust biosecurity measures as a baseline operational mandate and potentially constraining rapid innovation cycles across the market.

High Costs and Technical Complexity of Large-Scale Synthesis

The expense and technical challenges of producing long gene sequences constitute a critical market restraint, limiting accessibility and broad-scale adoption. According to Twist Bioscience’s disclosures, costs increase exponentially with sequence length due to synthesis errors and purification complexities, impeding applications requiring high-fidelity, large DNA constructs. This cost barrier deters smaller biotech firms and academic researchers from advancing large-gene applications, consolidating market control with well-funded entities. Consequently, companies must invest in process optimization and error-correction technologies to enhance yield and affordability. As demand for complex synthetic genes grows, overcoming these technical and financial hurdles remains pivotal; incremental innovations in enzymatic synthesis and automation are expected to gradually ease cost pressures, but substantial reductions will not materialize immediately.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
Increasing demand for synthetic genes in biotech applications	7.00%	Short term (≤ 2 yrs)	North America, Europe	Medium	Fast
Technological innovations in gene synthesis platforms	6.00%	Medium term (2–5 yrs)	Europe, Asia Pacific	Medium	Moderate
Expansion of research & industrial applications globally	8.60%	Long term (5+ yrs)	North America, Asia Pacific	Low	Slow

Regional Demand Dynamics

North America Market Statistics:

North America dominated the gene synthesis market in 2025, capturing approximately 39% of the global share and exhibiting the highest CAGR of 24.15%, making it the largest and fastest-growing region. This robust growth stems primarily from the expanding field of synthetic biology and intensified interest in gene therapy development. Key players such as Twist Bioscience and Integrated DNA Technologies have accelerated innovation by leveraging advanced automated synthesis platforms. Additionally, supportive policies from agencies like the U.S. National Institutes of Health (NIH) have streamlined research funding and regulatory pathways. The region’s strong infrastructure, coupled with substantial private and public investment, sustains an environment conducive to rapid technological and operational advancements. Consequently, North America remains a lucrative hub for gene synthesis, offering significant growth opportunities driven by escalating biomedical applications and an evolving regulatory landscape.

The United States anchors the North American gene synthesis market, spearheading innovation through a convergence of academic research and commercial enterprise. This market’s expansion mirrors the country’s leadership in synthetic biology, backed by federal funding initiatives such as the NIH's strategic investments in gene therapy research. Companies like Ginkgo Bioworks showcase strategic partnerships accelerating product development and commercialization. Regulatory clarity from the U.S. Food and Drug Administration (FDA) further bolsters confidence among stakeholders, enabling smoother clinical and commercial pipelines. These dynamics position the U.S. as a critical lever for regional market growth, reinforcing North America’s preeminence in gene synthesis innovation and applications.

Asia Pacific Market Analysis:

Asia Pacific emerged as the fastest-growing region in the gene synthesis market, registering a rapid growth with a CAGR of 14.2%. This robust expansion is primarily driven by accelerating investments in biotechnology research and increased adoption of synthetic biology techniques across pharmaceutical and agricultural sectors. The region’s dynamic innovation landscape, supported by government initiatives such as the Japan Agency for Medical Research and Development (AMED) and China’s National Key R&D Program, is fueling a surge in demand for customized gene synthesis solutions. Moreover, growing collaborations between academic institutions and industry players are enhancing operational efficiencies and driving cost-effective production. Asia Pacific’s agile regulatory adaptations, combined with expanding infrastructure and a highly skilled technical workforce, provide a fertile ground for technological advancements. These factors position the region as a strategic hub, offering significant opportunities for investors and companies aiming to capitalize on next-generation genetic engineering applications.

Japan holds a pivotal role within the Asia Pacific gene synthesis market, leveraging its advanced research ecosystem and stringent regulatory frameworks that ensure high product standards. The nation’s commitment to precision medicine and regenerative therapies is evident from organizations like RIKEN and the Pharmaceuticals and Medical Devices Agency (PMDA) that actively support innovation in gene synthesis. Japanese pharmaceutical companies also demonstrate strong purchasing power with a preference for high-quality, reliable gene synthesis services, reflecting in strategic partnerships with global biotech firms. This environment fosters a mature market with a focus on sustainable and reproducible genetic solutions. Japan’s disciplined approach to regulatory compliance and its emphasis on cutting-edge genetic technologies underscore its critical contribution to the region’s burgeoning gene synthesis sector.

China’s gene synthesis market is characterized by rapid scaling and widespread adoption, underpinned by significant government-backed funding and expansive biotechnology clusters such as those in Beijing and Shanghai. The Ministry of Science and Technology’s initiatives facilitate streamlined regulatory pathways and foster public-private partnerships, accelerating commercial applications of synthetic genes in medicine, agriculture, and environmental sectors. Increasing local manufacturing capabilities and investments by leading companies like BGI Group enhance competitive pricing and supply chain robustness. Furthermore, China’s younger demographic and expanding biotech talent pool fuel innovation and technology diffusion, making the market highly responsive to emerging global trends. China’s decisive role in amplifying regional R&D and production capacities makes it a strategic growth engine for the Asia Pacific gene synthesis market.

Europe Market Trends:

Europe maintained a notable presence in the gene synthesis market, driven by its robust life sciences infrastructure and progressive regulatory environment that fosters innovation. The region’s moderate growth reflects shifting demand towards tailored genetic solutions in pharmaceuticals and biotechnology, supported by increased funding from the European Commission’s Horizon Europe program. Additionally, stringent quality standards imposed by the European Medicines Agency encourage adoption of high-precision synthesis technologies. Operational advancements within regional biotech clusters, especially in the UK and the Netherlands, enhance collaborative research efficiency. Supply chain resilience, bolstered by diversified sourcing and localized manufacturing hubs, further sustains market momentum. Europe’s skilled workforce and emphasis on sustainable biomanufacturing position the region for continued expansion, as highlighted in recent corporate releases from gene synthesis leaders such as Twist Bioscience and Eurofins Genomics. These dynamics signal ample opportunities for stakeholders aiming to capitalize on Europe’s evolving gene synthesis landscape.

Germany plays a leading role in Europe’s gene synthesis market, leveraging its strong biopharma sector and extensive research collaborations. The country’s commitment to precision medicine and gene therapy has catalyzed demand for custom gene synthesis services, with federal initiatives like the German Center for Diabetes Research enhancing genomic research capabilities. Companies such as Merck KGaA have emphasized advancing synthesis platforms through digital integration and automation, as indicated in their 2023 press releases. Germany’s rigorous but clear regulatory framework facilitates clinical applications, attracting investments across the gene synthesis value chain. This environment underpins Germany’s strategic position in pushing region-wide innovation, making it a critical component of Europe’s moderate growth trajectory.

France contributes significantly to the gene synthesis market in Europe by capitalizing on its strong governmental support for biotech innovation and emerging startup ecosystems. The country’s public-private partnerships, exemplified by the French National Institute of Health and Medical Research (INSERM) collaborations, foster rapid adoption of synthetic biology tools in healthcare and agriculture. Regulatory adaptations supporting genetic engineering applications have improved commercialization pathways, encouraging local and international companies to expand operations. For instance, Integrated DNA Technologies (IDT) announced enhanced service capabilities in Paris in 2023, reflecting growing market confidence. France’s dynamic innovation culture and focused investments signal broader regional opportunities, reinforcing Europe’s moderate growth outlook in the gene synthesis market.

No card data available for this language/report.

Segment Leadership and Growth Trends

  Analysis by Method

Oligonucleotides held the largest share in the gene synthesis market in 2025, driven by their extensive use across research and diagnostic workflows. This segment’s leadership is anchored in the increasing demand for precise and rapid oligonucleotide synthesis, pivotal for PCR, gene editing, and molecular diagnostics. Institutions like the U.S. National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC) emphasize oligonucleotide applications in disease detection and personalized medicine, reinforcing adoption. Supply chain advances ensuring high-quality reagents and automated synthesizers support operational efficiencies, meeting evolving preferences for accuracy and speed. Established players can leverage their technological expertise, while emerging firms benefit from innovation niches in custom oligo design. Given sustained investments in molecular diagnostics and expanding applications, the oligonucleotides segment is poised to maintain its dominant position as research intensity and clinical demand grow.

Analysis by Type

Gene library synthesis represented the largest share in the gene synthesis market in 2025, driven by rising demand for comprehensive gene libraries essential to high-throughput genomic analysis. Leadership in this segment stems from the critical role gene libraries play in functional genomics, drug discovery, and synthetic biology, fostering tailored biological insights. Regulatory frameworks promoting genomics research, such as the European Union’s Horizon initiatives, encourage expansive library creation and utilization. Furthermore, digital transformation in bioinformatics facilitates sophisticated library design and quality control, aligning with growing customer expectations for integrated solutions. This segment offers strategic opportunities to established firms through portfolio expansion and for startups via specialized library customization. With the increasing adoption of large-scale genomic screening approaches, gene library synthesis remains integral to innovation pipelines across biotech and pharmaceutical sectors.

Analysis by Component

Product held the largest share in the gene synthesis market in 2025, supported by robust sales of synthesis instruments and reagents central to gene construction workflows. The prominence of this segment is propelled by advances in automated synthesizers and high-purity reagent kits, enabling faster and more reliable gene synthesis processes. Companies like Thermo Fisher Scientific and Agilent Technologies continuously announce innovations that strengthen supply chains and reduce turnaround times, meeting the exacting demands of researchers and manufacturers. Competitive dynamics favor suppliers who can deliver integrated, user-friendly platforms that enhance throughput and reproducibility. Both mature and emerging companies stand to benefit by expanding offerings aligned with sustainable manufacturing and digital integration. As gene synthesis complexity grows, investment in products will remain crucial for maintaining operational excellence and supporting expanding applications in research and therapeutics.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
Method	Oligonucleotides, Gene Assembly
Type	Gene Library Synthesis, Custom Gene Synthesis
Component	Product, Services
Application	Research and Development, Diagnosis, Therapeutics, Others

Competitive Landscape and Market Positioning

Key players in the gene synthesis market include Thermo Fisher Scientific, Twist Bioscience, Eurofins Genomics, Integrated DNA Technologies, GenScript, Agilent Technologies, Syntezza Bioscience, Bioneer, Sangon Biotech, and BioBasic. These companies represent a diverse geographic footprint, spanning North America, Europe, and Asia-Pacific, underscoring the global nature of innovation in gene synthesis. Firms like Thermo Fisher and Twist Bioscience are acknowledged for their technological leadership and broad service portfolios, while GenScript and Bioneer reflect the rising influence of Asian biotechnology firms. Eurofins Genomics and Integrated DNA Technologies contribute substantial expertise in quality control and custom synthesis, enhancing market reliability. Collectively, these players maintain a substantial edge through specialized capabilities, extensive distribution networks, and established reputations in synthetic biology, influencing trends and setting industry standards.

The competitive landscape is marked by dynamic shifts driven by collaborations and product innovations among the top companies. For instance, investments in high-throughput synthesis platforms and streamlined workflows are evident across key players, enhancing scalability and reducing turnaround times. Partnerships aimed at integrating gene synthesis with downstream applications in therapeutics and diagnostics are recalibrating service offerings to meet evolving customer needs. Additionally, technology refinement, such as advancing enzymatic synthesis and error-correction methods, strengthens differentiation. Companies are consolidating expertise and expanding geographically through strategic alignments, which not only amplify their competitive advantage but also accelerate the pace of innovation, catering to increasingly complex research demands.

Strategic / Actionable Recommendations for Regional Players

In North America, market participants should focus on expanding collaborative networks with research institutions and pharmaceutical innovators to integrate gene synthesis into emerging precision medicine pipelines. Harnessing next-generation automation technologies can further optimize production efficiency and responsiveness to bespoke project demands.

Asia Pacific players could benefit from deepening inter-regional partnerships to leverage the growing biopharmaceutical ecosystem, particularly by targeting fast-growing infectious disease and agricultural biotech segments. Investing in platform scalability and localized service customization will enhance competitive positioning.

European entities are advised to strengthen alliances with regulatory bodies and innovation clusters, which could facilitate streamlined development of high-fidelity synthesis products tailored for personalized medicine. Emphasizing environmental sustainability in process innovations may also differentiate offerings in this mature market.